Agios

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Agios and other ETFs, options, and stocks.

About AGIO

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. 

CEO
Brian M. Goff
CEOBrian M. Goff
Employees
540
Employees540
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2007
Founded2007
Employees
540
Employees540

AGIO Key Statistics

Market cap
1.79B
Market cap1.79B
Price-Earnings ratio
-4.28
Price-Earnings ratio-4.28
Dividend yield
Dividend yield
Average volume
1.48M
Average volume1.48M
High today
$33.34
High today$33.34
Low today
$29.81
Low today$29.81
Open price
$33.34
Open price$33.34
Volume
2.10M
Volume2.10M
52 Week high
$46.00
52 Week high$46.00
52 Week low
$22.24
52 Week low$22.24

Stock Snapshot

As of today, Agios(AGIO) shares are valued at $29.81. The company's market cap stands at 1.79B, with a P/E ratio of -4.28.

As of 2026-08-02, Agios(AGIO) stock has fluctuated between $29.81 and $33.34. The current price stands at $29.81, placing the stock 0.0% above today's low and -10.6% off the high.

Agios(AGIO) shares are trading with a volume of 2.1M, against a daily average of 1.48M.

In the last year, Agios(AGIO) shares hit a 52-week high of $46.00 and a 52-week low of $22.24.

In the last year, Agios(AGIO) shares hit a 52-week high of $46.00 and a 52-week low of $22.24.

AGIO News

TipRanks 1d
Agios Pharma Q4 2022 Earnings Report - Results, Call & Slides - TipRanks

...

Agios Pharma Q4 2022 Earnings Report - Results, Call & Slides - TipRanks
Simply Wall St 2d
Agios Pharmaceuticals Stock Sinks As Cash Burn Clouds Mitapivat Ramp

Agios Pharmaceuticals investors woke up to a painful reset. The stock dropped 8.3% to close at US$30.02, extending a weak one month stretch. At the same time, t...

Agios Pharmaceuticals Stock Sinks As Cash Burn Clouds Mitapivat Ramp
TipRanks 2d
Agios Pharmaceuticals price target raised to $52 from $46 at Citi

Citi raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $52 from $46 and keeps a Buy rating on the shares. The firm views the Q2 report as strong...

Analyst ratings

70%

of 10 ratings
Buy
70%
Hold
30%
Sell
0%

More AGIO News

Simply Wall St 6d
Agios Pharmaceuticals Is Down 7.7% After Halting Tebapivat While Advancing Mitapivat in Sickle Cell Disease – Has The Bull Case Changed?

Agios Pharmaceuticals recently reported topline Phase 2 results for tebapivat in sickle cell disease and, citing insufficient differentiation versus other pyruv...

Agios Pharmaceuticals Is Down 7.7% After Halting Tebapivat While Advancing Mitapivat in Sickle Cell Disease – Has The Bull Case Changed?

People also own

Based on the portfolios of people who own AGIO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.